New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
12:40 EDTBBY, CLWR, S, ZAGG, MBI, BAC, RIGL, AZN, ALLTOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday, extending the slide that began late yesterday following Ben Bernanke's press conference. House Speaker John Boehner and Senate Majority Leader Harry Reid both held press conferences within about the last hour, bringing the fiscal cliff fight back to the forefront of investors' minds... ECONOMIC EVENTS: In the U.S., weekly jobless claims fell 29,000 to 343,000, versus expectations for a drop to 369,000. Producer prices in the month of November fell 0.8%, versus an expected decline of 0.5%. "Core" prices, excluding food and energy, rose 0.1%, which matched expectations. Retail sales rose 0.3% in November, which missed expectations for an increase of 0.5%. In Europe, the region's finance ministers approved the long-delayed release of financial aid to Greece. Also, an agreement was reached on the foundation of a true banking union with ECB oversight... COMPANY NEWS: Best Buy (BBY) jumped over 15% after Minneapolis' Star Tribune said the company's founder Richard Schulze may make a fully financed $5B-$6B buyout offer by the end of the week... Clearwire (CLWR) rose nearly 14% to $3.13 after Sprint (S) disclosed that it offered $2.90 per share for the remaining stake in the company it does not already own. Clearwire said that its talks with Sprint are ongoing... MAJOR MOVERS: Among the notable gainers were ZAGG (ZAGG), up 15% after announcing a $10M share repurchase program, and MBI (MBIA), up 6.5% following positive analyst commentary about the potential for a settlement with Bank of America (BAC). Among the noteworthy losers was Rigel Pharmaceuticals (RIGL), which fell almost 35% after an RA drug it is developing in partnership with AstraZeneca (AZN) failed to meet one of its endpoints in a trial. Shares of AstraZeneca, meanwhile, fell 2.6%. Also lower were shares of Allot Communications (ALLT), down over 11% following a downgrade to Hold at Wunderlich... INDICES: Near 12:30 pm ET, the Dow was down 19.89, or 0.15%, to 13,225.56; the Nasdaq was down 21.52, or 0.71%, to 2,992.29; and the S&P 500 was down 7.47, or 0.52%, to 1,421.01.
News For BBY;CLWR;S;ZAGG;MBI;BAC;RIGL;AZN;ALLT From The Last 14 Days
Check below for free stories on BBY;CLWR;S;ZAGG;MBI;BAC;RIGL;AZN;ALLT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 21, 2014
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
06:43 EDTBACRegulators up bank warning efforts for poor risk assessment, Reuters says
Subscribe for More Information
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
18:29 EDTBACBofA, JPMorgan weigh plans to raise salaries for junior bankers, Bloomberg says
Subscribe for More Information
17:12 EDTBACOn The Fly: Closing Wrap
Subscribe for More Information
14:35 EDTBACBofA reaches $17B settlement over mortgage backed securities sales, AP says
Bank of America along with federal and state authorities agreed upon a $17B settlement for the bank in connection with the sale of mortgage-backed securities in the run-up to the 2008 financial crisis, says AP. Reference Link
14:20 EDTBACBofA reaches $17B settlement over mortgage backed securities sales, AP says
08:38 EDTBACRevolution Lighting enters loan, security agreement with BofA
Revolution Lighting (RVLT) announced that it has entered into a three year loan and security agreement with Bank of America (BAC). The agreement allows Revolution Lighting to borrow up to $25M on a revolving basis. Borrowings under the agreement are determined on specified percentages of eligible receivables and inventory, and bear interest either on the base rate plus specified margins or at LIBOR plus specified margins, at the election of Revolution Lighting. The loan provides Revolution Lighting with favorable interest rates with an initial interest rate of 3%. The agreement contains customary covenants and restrictions typical of these agreements.
August 19, 2014
12:42 EDTSOn The Fly: Midday Wrap
The market opened higher as it extended its gains from yesterday. Better than expected economic data on housing and consumer prices, as well as easing geopolitical tensions, has helped aid investor optimism. The market drifted higher throughout the morning with the Dow leading the way, followed by the Nasdaq, which is now near fourteen-year highs. The S&P is mostly higher, with the telecom services group being the lone sector showing losses, down just fractionally. ECONOMIC EVENTS: Housing starts for July rose to an annualized pace of 1.093M units, up from 0.945M units in June, and beating expectations for 0.963M units... The Consumer Price Index increased 0.1% overall, matching expectations. Less food and energy, the CPI was up 0.1%, which was also in-line with the consensus forecast. COMPANY NEWS: Shares of home improvement retailer The Home Depot (HD) are up more than 6% after the company posted better than expected second quarter results and raised its full year profit outlook... Shares of Sprint (S) are down 4% after Jefferies lowered its price target for Sprint shares to $4, saying it continues to see downside to estimates. MAJOR MOVERS: Shares of Skilled Healthcare (SKH) are up more than 20% after combining with Genesis HealthCare In 100% stock deal... Shares of cosmetics and fragrance company Elizabeth Arden (RDEN) are down 24% after the company's fourth quarter results came in well below analysts' consensus estimates. INDEXES: Near midday, the Dow was up 76.92, or 0.46%, to 16,915.66, the Nasdaq was up 12.96, or 0.29%, to 4,521.27, and the S&P 500 was up 8.49, or 0.43%, to 1,980.23.
07:39 EDTSSprint price target lowered to $4 from $7 at Jefferies
Jefferies lowered its price target for Sprint shares to $4 saying it continues to see downside to estimates. The firm expects a "muted response" to Sprint's new Family Pack pooled data plan and limited time promotion of waiving device access charges. It keeps an Underperform rating on the stock.
07:12 EDTSFCC looks into telecom special access line rates, Reuters says
Subscribe for More Information
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
06:20 EDTBACBofA COO transfers, senior manager assumes role, Bloomberg says
Subscribe for More Information
August 18, 2014
19:41 EDTSSprint CEO says regulators weren't set on industry consolidation, Bloomberg says
Sprint (S) recently dropped its bid seeking control of competitor T-Mobile (TMUS).
18:33 EDTSSprint introduces Sprint Family Share Pack data plan, doubles high-speed data
Subscribe for More Information
18:04 EDTSSprint to offer $100/month 20GB shared data plan through 2015, Bloomberg reports
Subscribe for More Information
11:06 EDTSSoftBank chooses Sharp as low-cost smartphone partner, WSJ reports
Subscribe for More Information
08:47 EDTSRaymond James to hold a summit
Subscribe for More Information
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:47 EDTBACU.S. banks consider Ireland fitting spot for EU divisions, FT says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use